The latest update is out from Creative Medical Technology Holdings ( (CELZ) ).
On September 24, 2026, Creative Medical Technology Holdings, Inc. strengthened its control over BioDefense, Inc. by acquiring 4,000,000 additional BioDefense common shares from Creative Acquisition Corp. for $200,000 in cash and 1,000,000 shares of its own stock. Following the transaction, the company now holds 16,000,000 BioDefense shares, representing 80% of BioDefense’s outstanding common stock, while CAC retains a 20% stake.
The deal consolidates Creative Medical Technology Holdings’ majority ownership in BioDefense and may enhance its strategic influence over the subsidiary’s operations and future direction. The transaction also underscores related-party governance considerations, as company CEO Timothy Warbington simultaneously serves as chairman and CEO of CAC and indirectly owns all of CAC’s stock, with the share issuance structured as a private placement under securities law exemptions.
This story was written using TipRanks’s AI tools and reviewed by a TipRanks editor.